iSono Health

Developer of an AI-driven portable and automated 3D breast ultrasound system for early breast cancer detection.

Website: https://isonohealth.com/

Cover Block

From the public record

Field Value
Name iSono Health
Tagline Developer of an AI-driven portable and automated 3D breast ultrasound system for early breast cancer detection. [iSono Health, November 2026]
Headquarters Sunnyvale, CA, United States [Crunchbase]
Founded 2015 [Crunchbase]
Stage Seed [Crunchbase]
Business model Hardware + Software
Industry Healthtech
Technology AI / Machine Learning
Geography North America
Growth profile Venture Scale
Founding team Maryam Ziaei, Shadi Saberi [Maryam Ziaei LinkedIn, September 2025] [Crunchbase]
Funding label $10M+
Total disclosed Approximately $14,700,000, company-reported cumulative venture and SBIR funding [iSono Health, November 2026]

Links

From the public record

The Short Version

PUBLIC iSono Health is building a portable, automated 3D breast ultrasound system, and it merits investor attention because it is pursuing a regulated imaging workflow that aims to reduce dependence on trained sonographers, a constraint that still limits breast imaging access in many care settings [Businesswire, May 2022] [iSono Health, November 2026]. The company was founded in 2015 and is based in Sunnyvale, California, with Maryam Ziaei and Shadi Saberi listed as co-founders across company and profile sources [Crunchbase] [LinkedIn].

The product, ATUSA, is described by the company as an AI-driven, wearable breast scanner that automates 3D ultrasound image capture at the point of care; the most defensible public milestone is U.S. FDA clearance for breast imaging, announced in May 2022 [Businesswire, May 2022] [iSono Health, November 2026]. The commercial proposition appears to rest on standardization and operator independence rather than on a conventional cart-based ultrasound workflow, with the company stating that scans can be acquired without a trained ultrasound operator [iSono Health, November 2026] [iSono Health].

On the team, public profiles identify Ziaei as co-founder and CEO and Saberi as co-founder and CTO, while Crunchbase attributes prior NIH SBIR/STTR reviewer experience to Ziaei and prior engineering roles at Broadcom and Intel to Saberi [LinkedIn, 2026] [Crunchbase]. That mix is relevant here because the company is selling a hardware-plus-software medical device, where regulatory execution and product engineering tend to matter as much as distribution ambition [Businesswire, May 2022].

Capital formation is somewhat harder to reconcile from public sources than the product story. Company materials say iSono Health has raised $14.7 million in venture and SBIR funding, while WISH separately reports $7.7 million in equity financing and $3.7 million in grants; other databases point to a $3 million seed round in 2025 and an undisclosed October 2025 investment from JSK Investments Group [iSono Health, November 2026] [Vestbee, October 2025]. The business model is best understood as hardware plus software in breast imaging, with commercial upside dependent on converting regulatory clearance into sustained clinical adoption [Crunchbase] [iSono Health, November 2026].

Over the next 12 to 18 months, the central questions are commercial proof and channel quality rather than product novelty alone. Public materials reference a distribution partnership spanning 31 countries and a customer pipeline of roughly 600, but those claims remain thinly corroborated, so investors should watch for named deployments, evidence of repeat purchasing, and clearer separation between pipeline, active installs, and revenue-bearing accounts [WISH, November 2025] [iSono Health, November 2026].

Unconfirmed -- This section relies materially on company statements and database profiles, with independent confirmation strongest for founding, headquarters, and FDA clearance, but weaker for funding totals, commercial release, and pipeline claims.

Taxonomy Snapshot

Axis Value
Stage Seed
Business Model Hardware + Software
Industry / Vertical Healthtech
Technology Type AI / Machine Learning
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding $10M+ (total disclosed ~$14,700,000)

The Company in Brief

PUBLIC The public record is thin on narrative detail, but the core company facts are consistent enough to sketch the outline. iSono Health is a Sunnyvale, California medtech startup founded in 2015, according to its Crunchbase company profile, and its website presents the company around ATUSA, an AI-driven portable and automated 3D breast ultrasound scanner positioned for point-of-care breast imaging [Crunchbase] [iSono Health, November 2026].

The founding team shown in public profiles centers on Maryam Ziaei, listed on LinkedIn as co-founder and CEO, and Shadi Saberi, listed as co-founder and CTO [Crunchbase] [LinkedIn, 2026]. On the company website, iSono Health frames its operating wedge in practical terms: automated 3D ultrasound scans intended to capture the full breast volume without requiring a trained ultrasound operator, with image review software layered on top [iSono Health, November 2026].

Chronology is clearer on product and financing than on the legal entity itself. The most concrete public milestone is FDA clearance for the ATUSA System for breast imaging, reported in May 2022 [Businesswire, May 2022]. More recently, the company website says ATUSA has been commercially released and that iSono Health has raised $14.7 million in venture and SBIR funding, while Crunchbase and other startup databases reflect investor participation from firms including Draper Associates and DHVC, among others [iSono Health, November 2026] [Crunchbase]. The available public sources used here do not establish the legal entity name or state incorporation with enough confidence to include them as fact.

Single-source, plausible -- Confirmed in part by Crunchbase and the company website; milestone support is mixed, with some material claims resting on company-reported disclosures.

What They Have Built

MIXED

The product story here is relatively clear, even if some of the performance and commercialization detail remains company-reported. iSono Health describes ATUSA as a portable, automated 3D breast ultrasound system built around a wearable scanner, with imaging intended to be captured at the point of care without a trained ultrasound operator [iSono Health, November 2026]. A May 2022 Business Wire announcement reported that the ATUSA System received U.S. FDA clearance for breast imaging, which is the strongest independently identified signal on regulatory status in the available record [Business Wire, May 2022].

Public descriptions of the system are directionally consistent across sources, though not equally well verified. The company website says the scanner automatically captures the entire breast volume and is designed to deliver repeatable imaging for diagnosis and monitoring [iSono Health, November 2026]. Secondary research summarizes the product as combining wearable hardware, automated 3D ultrasound, a Windows application for image display, and a secure web application for remote viewing [Healthcare Discovery]. Those software-layer details should be read as descriptive rather than independently validated, and the same caution applies to company claims that scans take about one to two minutes per breast and that image acquisition can be performed by physicians, nurses, or medical assistants rather than specialist sonographers [iSono Health, November 2026].

What stands out, on the evidence available, is the attempt to standardize breast ultrasound acquisition rather than simply add another imaging interface. If the operator-independence claim holds in routine use, the product could widen where breast ultrasound can be performed, particularly in sites that lack trained sonographers or conventional imaging infrastructure [iSono Health, November 2026]. A current Rippling posting for a Senior Software Engineer also points to continued work spanning robotic 3D quantitative ultrasound, AI, and breast imaging, which supports, but does not fully map, the technical stack implied by public materials [Rippling].

Single-source, plausible -- Core product category and FDA clearance are supported by company materials and Business Wire, while workflow, timing, and software-component details rely partly on company or secondary-source descriptions.

Market Size and Demand

PUBLIC

Breast imaging is drawing renewed attention because providers are under pressure to expand access while preserving diagnostic consistency, and iSono Health is aimed at the part of the workflow where operator dependence still constrains throughput and setting flexibility [Businesswire, May 2022] [iSono Health, November 2026].

The available public record does not include a named third-party TAM, SAM, or SOM study for iSono Health’s exact category, which is best described as automated breast ultrasound delivered through a portable hardware and software stack. What is visible instead is the company’s positioning around point-of-care breast imaging, repeatable 3D scans, and use by physicians, nurses, and medical assistants rather than specialist sonographers [iSono Health, November 2026]. That matters because the relevant market is not only breast ultrasound hardware, but also a broader access-and-workflow layer inside women’s imaging, especially where trained sonography staff or fixed imaging infrastructure are scarce [iSono Health, November 2026] [Vestbee, October 2025].

Demand drivers in the cited material are practical rather than speculative. The company and secondary coverage consistently frame ATUSA around standardized image acquisition without a trained ultrasound operator, which suggests the wedge is labor substitution, site expansion, and repeatability rather than a new reimbursement category [iSono Health, November 2026] [Vestbee, October 2025]. Public materials also point to international distribution ambitions across 31 countries through Abdul Latif Jameel Health, which indicates management sees unmet demand outside the traditional hospital imaging core, particularly in regions where specialist capacity is uneven [Vestbee, October 2025].

Adjacent markets matter here because iSono Health is selling into a clinical decision chain that already includes conventional handheld ultrasound, cart-based breast ultrasound, mammography, and, in higher-acuity pathways, MRI. On the evidence available, ATUSA appears to compete less as a direct replacement for every imaging modality and more as a substitute for operator-intensive ultrasound acquisition in screening and monitoring use cases [iSono Health, November 2026] [Businesswire, May 2022]. That framing is important for market sizing discipline: the nearer addressable opportunity is likely the subset of breast imaging encounters where automation, portability, and non-sonographer operation are valuable, not the entirety of breast cancer diagnostics.

Regulatory and macro forces are supportive, but the support is uneven. FDA clearance is a meaningful gate in this category and the company’s U.S. clearance in 2022 reduces one major commercialization obstacle [Businesswire, May 2022]. At the same time, public evidence here does not establish reimbursement breadth, procurement velocity, or deployment density, which means market readiness should be read as conditional on hospital and clinic adoption behavior rather than on clearance alone [Businesswire, May 2022] [WISH, November 2025].

Cited market signal Figure Relevance
Cumulative venture and SBIR funding reported by company $14.7M Indicates investor and grant-backed interest in the category, though company-reported [iSono Health, November 2026]
Equity financing reported by WISH $7.7M Suggests third-party recognition of financability, but does not size end-market demand [WISH, November 2025]
Non-dilutive grants reported by WISH $3.7M Points to public-sector support for clinical and technical development [WISH, November 2025]
Reported customer pipeline Approximately 600 A demand indicator, though pipeline is not equivalent to deployments or revenue [WISH, November 2025]
Countries covered by distribution partnership 31 Signals geographic ambition and a cross-border access thesis [Vestbee, October 2025]

The table is narrower than a classic market map, but that is the honest shape of the evidence. Public sources support demand signals and distribution intent more clearly than they support formal market size, so the market case rests on workflow pain and access expansion rather than on a verified top-down TAM model.

Unconfirmed -- This section relies materially on company-reported positioning and one secondary profile for pipeline and distribution claims, with FDA clearance corroborated by Businesswire.

Who Else Is Fighting for This

MIXED iSono Health appears to sit less in a head-to-head startup scrum than in a contested workflow between standard breast ultrasound, mammography-led screening pathways, and whichever device makers can make breast imaging easier to acquire outside specialist radiology settings [iSono Health, November 2026] [Businesswire, May 2022].

The public record is thin on named direct startup peers, which matters here because the company is selling into an established imaging stack rather than creating a category from scratch. On the incumbent side, conventional breast ultrasound and mammography remain the practical alternatives embedded in hospital and imaging-center workflows, with trained sonographers and radiology departments controlling image acquisition in the standard model [iSono Health, November 2026]. On the challenger side, iSono Health is positioning ATUSA as an automated 3D breast-ultrasound system that reduces dependence on trained ultrasound operators, a claim the company makes in its own materials and that sits at the core of its wedge into lower-resource or point-of-care settings [iSono Health, November 2026] [Vestbee, October 2025]. The adjacent substitute is not another startup so much as the status quo: referral out to existing imaging infrastructure.

The company does have a visible edge, but it is narrower than the homepage language suggests. ATUSA has U.S. FDA clearance for breast imaging, which is a meaningful regulatory threshold in a hardware-heavy category and can slow down would-be entrants that still need validation, clearance work, and commercial packaging [Businesswire, May 2022]. The product case also rests on automation, repeatability, and portability, with the company stating that scans can be acquired without a trained ultrasound operator and viewed through associated software tools [iSono Health, November 2026]. That edge is durable to the extent it is tied to device integration, workflow design, and regulatory approvals; it is perishable to the extent distribution and customer trust still need to be built market by market, especially because the strongest commercial claims, including commercial release and a broad customer pipeline, remain company-reported or lightly corroborated [iSono Health, November 2026] [WISH] [Vestbee, October 2025].

The main exposure is less a single startup rival than the installed base of incumbent imaging pathways and the procurement friction that comes with medical devices. A clinic deciding between ATUSA and existing referral patterns is also deciding whether to adopt a new hardware platform, train staff around a new imaging workflow, and trust automated acquisition quality at the point of care [iSono Health, November 2026]. If that workflow change stalls, established radiology-centered channels are the effective winner by default. The other visible exposure is evidence depth: FDA clearance helps, but the available public materials do not yet name a broad set of verified health-system customers or deployment sites, which limits the public case that iSono Health has already crossed from technical validity into repeatable commercial pull [Businesswire, May 2022] [WISH].

The most plausible 18-month scenario is that competitive outcomes hinge on channel execution rather than pure product novelty. iSono Health could be the winner if its reported distribution partnership across 31 countries translates into actual placements and if operator-independent acquisition resonates in clinics that lack specialist sonography staff [Vestbee, October 2025]. The loser if that does not happen is iSono Health itself, because in that case the category does not wait for a startup alternative, it reverts to incumbent ultrasound and mammography workflows that already own physician referral behavior and reimbursement familiarity. With no publicly sourced named direct rival in the input set, the practical competitive benchmark remains the existing imaging pathway, not a clearly identified venture-backed peer.

Single-source, plausible -- Core product positioning is corroborated by iSono Health materials and FDA-clearance coverage from Businesswire, but direct named competitor evidence is absent from the provided public source set and several commercial claims remain company-reported or lightly corroborated.

Opportunity

Upside Case

PUBLIC The prize here is not a marginally better imaging tool, but a chance to become the operator-light breast ultrasound platform that expands access well beyond conventional specialist workflows, if iSono Health can turn FDA clearance, automation, and early distribution into repeatable deployment at scale [Businesswire, May 2022] [iSono Health, November 2026] [Vestbee, October 2025].

The headline opportunity is straightforward. If ATUSA can do in routine practice what the company says it does on paper, namely automate breast image acquisition in a portable, wearable form factor that does not depend on a trained sonographer, iSono Health could occupy a distinct position between legacy ultrasound hardware and higher-cost imaging infrastructure [iSono Health] [Businesswire, May 2022]. That outcome is reachable rather than purely aspirational because three pieces are already visible in public sources: a cleared product, not just a prototype [Businesswire, May 2022]; a stated commercial release [iSono Health, November 2026]; and a reported distribution partnership spanning 31 countries across the Middle East and North Africa, Africa, South Asia, and Southeast Asia, which suggests management is pursuing geographic use early rather than relying only on direct domestic sales [Vestbee, October 2025].

The paths to scale are still narrow, but they are legible enough to frame as scenarios rather than abstractions.

Scenario What happens Catalyst Why it's plausible
Point-of-care standardization ATUSA becomes a default breast ultrasound option in physician offices and women's health clinics that lack specialist sonography capacity Wider commercial rollout after FDA clearance and company-reported commercial release [Businesswire, May 2022] [iSono Health, November 2026] The product is specifically positioned around automated acquisition and use by physicians, nurses, and medical assistants rather than specialist sonographers [iSono Health]
Cross-border distribution scale The company grows faster outside the US through channel partners in under-served imaging markets Execution of the reported Abdul Latif Jameel Health distribution partnership across 31 countries [Vestbee, October 2025] Public materials consistently frame ATUSA around access, portability, and reduced dependence on trained operators, which is a tighter fit for capacity-constrained care settings than for tertiary imaging centers [Vestbee, October 2025] [iSono Health]
Data and workflow platform iSono Health evolves from selling a device into owning an imaging workflow layer tied to standardized 3D scans, remote review, and follow-up monitoring More installed systems generating repeatable scans and use of the secure web application for remote viewing [iSono Health] The product bundle already includes hardware, image-display software, and a web application, which gives the company more surface area than a single-purpose device sale [iSono Health]

The compounding logic rests on standardization. If ATUSA truly produces repeatable automated scans and reduces operator dependence, each new site could lower adoption friction for the next one, because training requirements, workflow design, and image-acquisition consistency become more transferable across clinics [iSono Health]. The early hints of that flywheel are modest but visible: iSono Health has assembled both venture and non-dilutive backing, including reported NIH, NSF, and NCI support, and public profiles describe a customer pipeline of about 600, which, while company-adjacent and unverified as deployments, suggests interest is being generated ahead of broad market penetration [WISH, November 2025] [Health Technology Insights] [iSono Health, November 2026]. If even a fraction of those relationships convert, the company could accumulate a proprietary corpus of standardized breast-ultrasound scans and workflow data that is more defensible than the model layer alone.

The size of the win depends on whether iSono Health becomes a niche device vendor or a scaled imaging platform. Public sources provided here do not include a named public comparable, sector TAM study, or acquisition multiple that would support a defensible valuation range, so the upside is better expressed in strategic terms: if the cross-border distribution and point-of-care standardization scenarios both play out, iSono Health could plausibly become a meaningful breast-imaging platform with device, software, and clinical-workflow revenue attached, rather than a one-time capital equipment product (scenario, not a forecast) [Vestbee, October 2025] [iSono Health] [Businesswire, May 2022]. That is a large outcome in practical terms because breast imaging is a repeat-use clinical workflow, not a one-off diagnostic event, and the company is attempting to insert itself at the image-acquisition layer where behavior can become sticky once embedded.

Unconfirmed -- This section relies on a mix of independently reported FDA clearance and partnership references, but several material upside premises, including commercial release, product workflow, and pipeline scale, remain company-reported or sourced through company-adjacent profiles [Businesswire, May 2022] [iSono Health, November 2026] [WISH, November 2025].

Sources

From the public record

  1. [iSono Health, November 2026] iSono Health, Say Hello to ATUSA | https://isonohealth.com/

  2. [Crunchbase] iSono Health, Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/isono-health

  3. [Maryam Ziaei LinkedIn, September 2025] Maryam Ziaei, Health Innovation & Commercialization | https://www.linkedin.com/in/maryamziaei/

  4. [Businesswire, May 2022] iSono Health Announces FDA Clearance of the ATUSA System for Breast Imaging | https://www.businesswire.com/news/home/20220510005364/en/iSono-Health-Announces-FDA-Clearance-of-the-ATUSA-System-for-Breast-Imaging

  5. [LinkedIn, 2026] Maryam Ziaei, Health Innovation & Commercialization | https://www.linkedin.com/in/maryamziaei/

  6. [Vestbee, October 2025] JSK Investments backs US startup iSono Health to bring smart breast imaging to emerging markets | https://www.vestbee.com/blog/articles/jsk-investments-backs-us-startup-isono-health-to-bring-smart-breast-imaging-to-emerging-markets

  7. [iSono Health] iSono Health, Say Hello to ATUSA | https://isonohealth.com/

  8. [Healthcare Discovery] iSono Health, Wearable 3D Breast Ultrasound, FDA Record and Evidence | https://healthcarediscovery.ai/companies/isono-health/

  9. [Rippling] Senior Software Engineer at iSono Health | https://ats.rippling.com/isono-health/jobs

  10. [WISH, November 2025] iSono Health | https://platform.wish.org/company/isono-health

  11. [WISH] iSono Health | https://platform.wish.org/company/isono-health

  12. [Health Technology Insights] iSono Health | https://www.hti.health/healthtech-companies/isono-health

Articles about iSono Health

View on Startuply.vc